Strong scientific consensus on lengthy development timelines underpins the 93% market-implied odds against a hantavirus vaccine becoming available in 2026. All active candidates, including mRNA platforms from Moderna-Korea University collaborations and DNA-based approaches targeting glycoproteins, remain in preclinical or early Phase 1 stages as of mid-2026, with no candidates advancing to pivotal efficacy trials. A May 2026 cruise-ship outbreak involving Andes virus highlighted the absence of licensed options outside limited South Korean use of Hantavax, prompting renewed research interest but not regulatory acceleration. Standard vaccine pathways require multiple years for safety, immunogenicity, and manufacturing scale-up, even with historical precedents like DNA vaccine Phase 1 data showing neutralizing antibodies. Traders appear to discount rapid emergency pathways absent unprecedented prioritization, though unexpected trial breakthroughs or funding surges could narrow the gap before year-end.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$116,333 Vol.
$116,333 Vol.
31 dic 2026
$116,333 Vol.
$116,333 Vol.
31 dic 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Strong scientific consensus on lengthy development timelines underpins the 93% market-implied odds against a hantavirus vaccine becoming available in 2026. All active candidates, including mRNA platforms from Moderna-Korea University collaborations and DNA-based approaches targeting glycoproteins, remain in preclinical or early Phase 1 stages as of mid-2026, with no candidates advancing to pivotal efficacy trials. A May 2026 cruise-ship outbreak involving Andes virus highlighted the absence of licensed options outside limited South Korean use of Hantavax, prompting renewed research interest but not regulatory acceleration. Standard vaccine pathways require multiple years for safety, immunogenicity, and manufacturing scale-up, even with historical precedents like DNA vaccine Phase 1 data showing neutralizing antibodies. Traders appear to discount rapid emergency pathways absent unprecedented prioritization, though unexpected trial breakthroughs or funding surges could narrow the gap before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Mercado abierto: May 4, 2026, 10:39 AM ET
Volumen
$116,333Fecha de finalización
31 dic 2026Mercado abierto
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Strong scientific consensus on lengthy development timelines underpins the 93% market-implied odds against a hantavirus vaccine becoming available in 2026. All active candidates, including mRNA platforms from Moderna-Korea University collaborations and DNA-based approaches targeting glycoproteins, remain in preclinical or early Phase 1 stages as of mid-2026, with no candidates advancing to pivotal efficacy trials. A May 2026 cruise-ship outbreak involving Andes virus highlighted the absence of licensed options outside limited South Korean use of Hantavax, prompting renewed research interest but not regulatory acceleration. Standard vaccine pathways require multiple years for safety, immunogenicity, and manufacturing scale-up, even with historical precedents like DNA vaccine Phase 1 data showing neutralizing antibodies. Traders appear to discount rapid emergency pathways absent unprecedented prioritization, though unexpected trial breakthroughs or funding surges could narrow the gap before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volumen
$116,333Fecha de finalización
31 dic 2026Mercado abierto
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Strong scientific consensus on lengthy development timelines underpins the 93% market-implied odds against a hantavirus vaccine becoming available in 2026. All active candidates, including mRNA platforms from Moderna-Korea University collaborations and DNA-based approaches targeting glycoproteins, remain in preclinical or early Phase 1 stages as of mid-2026, with no candidates advancing to pivotal efficacy trials. A May 2026 cruise-ship outbreak involving Andes virus highlighted the absence of licensed options outside limited South Korean use of Hantavax, prompting renewed research interest but not regulatory acceleration. Standard vaccine pathways require multiple years for safety, immunogenicity, and manufacturing scale-up, even with historical precedents like DNA vaccine Phase 1 data showing neutralizing antibodies. Traders appear to discount rapid emergency pathways absent unprecedented prioritization, though unexpected trial breakthroughs or funding surges could narrow the gap before year-end.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes